Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
Posted inGastroenterology Internal Medicine news

Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice

The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasize the need for sham-controlled evidence in interventional gastroenterology.
Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD
Posted inDermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.
Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
Posted inGastroenterology news Oncology

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and manageable immunochemotherapy strategy for this high-risk population.